Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Follow-Up Questions
ZLDPF 주식의 가격 성능은 어떻습니까?
ZLDPF의 현재 가격은 $71.59이며, 전 거래일에 decreased 0% 하였습니다.
Zealand Pharma A/S의 주요 사업 주제나 업종은 무엇입니까?
Zealand Pharma A/S은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Zealand Pharma A/S의 시가총액은 얼마입니까?
Zealand Pharma A/S의 현재 시가총액은 $3.3B입니다
Zealand Pharma A/S는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 18명의 분석가가 Zealand Pharma A/S에 대한 분석 평가를 실시했으며, 이는 9명의 강력한 매수, 11명의 매수, 3명의 보유, 0명의 매도, 그리고 9명의 강력한 매도를 포함합니다
